Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Koichi Tomoshige (15304682) (author)
Kolejni autorzy:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
od: Nicholas T. Younger (14956251)
Wydane: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
od: Nicholas T. Younger (14956251)
Wydane: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
od: Nicholas T. Younger (14956251)
Wydane: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
od: Nicholas T. Younger (14956251)
Wydane: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
od: Dhruv Chachad (14954640)
Wydane: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
od: Dhruv Chachad (14954640)
Wydane: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
od: Dhruv Chachad (14954640)
Wydane: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
od: Dhruv Chachad (14954640)
Wydane: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
od: Dhruv Chachad (14954640)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
od: Man Xu (14963249)
Wydane: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
od: Caleb N. Seavey (15056489)
Wydane: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
od: Caleb N. Seavey (15056489)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_kom2d2f2dc38o8vnsr23oa9cms